Monday, 26 October 2026
Oral sickle cell treatment trial, Latvian alcohol harms decline, Ukraine maternity services depleted
- 01
Mitapivat investigated as oral treatment for sickle cell disease
Mitapivat, an oral pyruvate kinase activator, has been investigated as a potential disease-modifying treatment for people with sickle cell disease. Its novel mechanism is intended to ameliorate haemolytic anaemia. The source identifies RISE UP as a global phase 3, double-blind, randomised, placebo-controlled trial but provides limited detail and reports no efficacy or safety results.
via The Lancet
- 02
Latvian alcohol policy changes begin reducing direct health harms
Recent alcohol policy changes in Latvia are starting to reduce direct harms to health. The development is notable because Latvia has one of the world’s highest rates of alcohol consumption. The source gives limited detail about the policies or the scale of harm reduction.
via The Lancet
- 03
Conflict damages Ukraine maternity facilities and depletes workforce
Russia’s invasion and continuing conflict have damaged maternity care facilities in Ukraine and caused workforce shortages. The disruption affects the country’s capacity to provide maternity services. The Lancet report gives limited further detail.
via The Lancet
- 04
Structural barriers constrain primary care access for Indigenous men
Aboriginal and Torres Strait Islander men engaged with primary care when services were accessible, relevant, culturally safe and respectful, new research found. Reported barriers included long waits, appointment difficulties, limited access to male health professionals, confidentiality concerns, previous negative experiences and culturally inappropriate environments. Aboriginal Community Controlled Health Organisations and male-only outreach programs were identified as effective models because they combined community control, trusted relationships, flexibility and continuity of care. The researchers identified employing Aboriginal and Torres Strait Islander health workers, offering flexible appointments and outreach, and designing services with local men as key service features. The findings come amid an 8.8-year life-expectancy gap between Aboriginal and Torres Strait Islander men and non-Indigenous men, while potentially avoidable deaths before age 75 are almost three times as common.
- 05
Endovascular therapy trial for mild stroke appears ahead of print
A trial of endovascular therapy for mild stroke with large-vessel occlusion has appeared ahead of print in the New England Journal of Medicine. The supplied source does not report the trial design, participants, outcomes or findings. It therefore provides insufficient detail to assess whether endovascular therapy benefited this patient group or could affect acute referral pathways.
via NEJM
- 06
Thelaziasis report listed ahead of print in NEJM
A report titled “Thelaziasis” was listed ahead of print in the New England Journal of Medicine. The source provides no clinical details, findings or information about affected patients. No further faithful summary is possible from the limited text supplied.
via NEJM
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.